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Abstract 
Vitamin D from the diet or synthesized in the skin upon UV-B irradiation is converted in the 
organism into the active metabolite 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3, calcitriol), a 
pleiotropic hormone with wide regulatory actions. The classical model of 1,25(OH)2D3 action 
implies the activation of the vitamin D receptor, which binds specific DNA sequences in its 
target genes and modulates their transcription rate. We have recently shown that 1,25(OH)2D3 
induces the expression of the JMJD3 gene coding for a histone demethylase that is involved 
in epigenetic regulation. JMJD3 mediates the effects of 1,25(OH)2D3 on a subset of target 
genes and affects the expression of ZEB1, ZEB2 and SNAI1, inducers of epithelial-
mesenchymal transition. Novel data indicate that 1,25(OH)2D3 has an unanticipated wide 
regulatory action on the expression of genes coding for histone demethylases of the Jumonji C 
(JmjC) domain and lysine-specific demethylase (LSD) families. Moreover, JMJD3 
knockdown decreases the expression of miR-200b and miR-200c, two microRNAs targeting 
ZEB1 RNA. This may explain the upregulation of this transcription factor found in JMJD3-
depleted cells. Thus, 1,25(OH)2D3 exerts an ample regulatory effect on the expression of 
histone modifying enzymes involved in epigenetic regulation that may mediate its actions on 
gene transcription and cell phenotype. 
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Vitamin D regulates gene expression 
1α,25-dihydroxyvitamin D3 (1,25(OH)2D3, calcitriol) is the most active vitamin D metabolite 
in the organism and a pleiotropic hormone with ample regulatory actions.1 For decades, lack 
of adequate vitamin D levels has been linked to impaired intestinal calcium absorption and 
bone formation (rickets in children, osteomalacia in adults). However, during the past 
decades, 1,25(OH)2D3 is receiving an increasing interest as epidemiological studies suggest 
that vitamin D deficiency is associated with a higher risk of developing colon cancer and 
perhaps other neoplasias, and autoimmune and infectious diseases such as multiple sclerosis 
and tuberculosis.2-4 At the cellular level, 1,25(OH)2D3 modulates proliferation, differentiation, 
survival, metabolism and physiology, and potentiates the antitumoral activity of certain 
chemotherapeutic agents, in a cell-type- and -context-dependent manner.5-10 
According to the classical model of action, 1,25(OH)2D3 binds to and activates a 
transcription factor of the nuclear receptor superfamily, the vitamin D receptor (VDR), and 
modulates the transcription rate of its target genes.11 1,25(OH)2D3 is a major regulator of gene 
expression in higher organisms as VDR is expressed in at least 38 human cell types.12 In line 
with this, genome-wide studies using chromatin immunoprecipitation coupled with ultra high-
throughput sequencing (ChIP-Seq) have revealed a high number and variety of VDR binding 
sites in genes associated to many different cell functions and physiological and pathological 
conditions.13-16 
 This mechanism of action has progressively become more comprehensive and 
complex with the finding that VDR is partially located outside the cell nucleus where it 
mediates the effects of 1,25(OH)2D3 in the opening of ion channels and in the activity of 
enzymes such as kinases, phosphatases, and phospholipases.17 Remarkably, at least part of 
these extranuclear signaling pathways converges and contributes to the control of gene 
transcription by VDR.18,19 Moreover, 1,25(OH)2D3 regulates genes that seem to lack VDR 
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binding sites,15 and exerts post-translational gene regulatory effects by controlling the 
expression of multiple proteases and protease inhibitors.20 In addition, in certain systems 
VDR has been found to interact with other transcription regulators such as β-catenin and 
FoxO factors having ligand-dependent or -independent effects.21,22 
 
Histone demethylation  
The key role of epigenetic regulation, defined as chromatin changes affecting nucleosomal 
histones or DNA methylation, on transcription activation and repression is well recognized. 
The tails of the four core histones exposed on the nucleosome surface are subjected to a 
variety of enzyme-catalyzed post-translational modifications including acetylation, 
methylation, ubiquitylation, ADP-ribosylation, phosphorylation and sumoylation, which may 
occur singly or in combination.23,24 Histone methylation is more complex than any other post-
translational histone modification. It can occur on either lysines or arginines residues, and the 
consequence of its methylation can be either positive or negative towards transcriptional 
expression depending on the type of residue and on its position within the histone. Further 
complexity results from the fact that there can be multiple methylated states on each residue, 
as lysines can be mono- (me1), di- (me2) or tri- (me3) methylated, and arginines can be 
mono- or dimethylated.25,26 The methylation state can lead to different functional 
consequences, as effector proteins might recognize one modification and have little affinity 
for other on the same residue.27 Histone methylation is a reversible process mediated by two 
antagonizing groups of enzymes: histone methytransferases (HMT) and histone demethylases 
(HDM).27-29 Misregulation of histone modifications may lead to deregulation of gene 
expression and perturbation of cellular identity, which may contribute to cancer initiation, 
progression and/or metastasis.30,31 
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There are three distinct classes of enzymes capable of removing methylation marks. 
The first class includes peptidylarginine deiminase (PADI) enzymes that convert methylated 
residues of arginine to citrulline through a demethylimination reaction. Besides their clear role 
antagonizing methylarginine modifications, PADI enzymatic activity does not result in the 
production of an unmodified arginine, and for that fail to meet the requirements of a true 
HDM.27,32 Lysine specific demethylase (LSD)-1 was the founding member of the second class 
of enzymes and the first true demethylase to be described.33 The demethylation reaction 
catalyzed by LSDs limits these enzymes to use only mono- and dimethylated lysine residues 
as substrates.27,34 The third and largest group of HDM enzymes contains a Jumonji C (JmjC) 
domain and catalyzes site-specific demethylation of mono-, di- and trimethylated lysines and, 
in the case of one particular member (JMJD6), also the site-specific demethylation of mono- 
and dimethylated arginines.28,35,36 There are 30 proteins with a JmjC domain annotated in the 
human genome, although some of them are unlikely to be involved in histone 
demethylation.28 
 
Vitamin D modulates the expression of histone demethylase genes 
Recently, we have reported that 1,25(OH)2D3 regulates the RNA expression of the genes 
encoding for the JmjC domain-containing enzymes JMJD3 and JMJD4 in SW480-ADH 
human colon cancer cells. The RNA expression of a few other members of this group of 
enzymes such as PHF2, UTX, UTY, KDM5C/2A/3A, JMJD1C and MINA was unaffected by 
1,25(OH)2D3 treatment.37 As there was no literature for JMJD4, we focused our studies on 
JMJD3. This enzyme, also known as KDM6B, was the first specific demethylase of the 
trimethylated lysine 27 of histone H3 (H3K27me3) described.38-41 Together with another 
JmjC domain-containing enzyme, UTX, they are the only demethylases capable to eliminate 
the H3K27me3 mark.31,38-40 The presence of H3K27me3 at transcriptional sites usually 
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correlates with gene repression and the deregulation of this histone mark has been associated 
with cancer.42-44 
 Notably, we found that JMJD3 is induced by 1,25(OH)2D3 and partially mediates the 
transcriptional upregulation of a subset of 1,25(OH)2D3 target genes including CYP24A1, the 
tumor invasion suppressor CDH1/E-cadherin and the putative tumor suppressor CST5/cystatin 
D.37 Accordingly, JMJD3 depletion blocks the acquisition of an epithelial phenotype, the 
inhibition of cell proliferation and the antagonism of the Wnt/β-catenin signaling promoted by 
1,25(OH)2D3 in colon cancer cells.37 In addition, JMJD3 seems to have a role in the process of 
epithelial-mesenchymal transition (EMT), that is a crucial early step in metastasis,45,46 as 
JMJD3 depletion upregulates the expression of the EMT inducers SNAIL1, ZEB1 and ZEB2 
and the mesenchymal markers fibronectin-1 and LEF1, while it downregulates the epithelial 
proteins claudin-1 and claudin-7.37 Data obtained with samples from colon cancer patients 
indicate that JMJD3 RNA was downregulated in a 56% of patients correlating with low VDR 
and high SNAI1 RNA expression.37 Altogether, our data indicate that JMJD3 is a 
1,25(OH)2D3 target gene that, in turn, partially mediates the antitumoral effects of 
1,25(OH)2D3 on human colon cancer cells. 
 Now, we have extended the study of 1,25(OH)2D3 action to the LSDs and to all genes 
known to encode JmjC domain-containing enzymes. Quantitative RT-PCR analyses show that 
1,25(OH)2D3 induces the expression of HSPBAP1, JARID2 and KDM5B, while it 
downregulates that of KDM4A/4C/4D/5A/2B, HIF1AN, JMJD5/6, HR and PLA2G4B in 
SW480-ADH cells (Figure 1). In contrast, KDM4B/3B/5D, JMJD8, PHF8 and NO66 are not 
affected by 1,25(OH)2D3 treatment (Figure 1). Additionally, the expression of LSD1 and 
LSD2, the two members of the LSD family, is also induced by 1,25(OH)2D3 (Figure 1). De 
Santa et al.41 analyzed the expression of 27 JmjC domain-containing proteins in mouse 
macrophages and found that only two, JMJD3 and JARID2, that are induced by 1,25(OH)2D3 
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in SW480-ADH cells, were also upregulated upon bacterial lipopolysaccharide (LPS) 
stimulation. Several reports have shown that JMJD3 is regulated upon environmental stimuli 
(bacterial products, viruses, parasites and toxins),41,47-50 suggesting that it may bridge 
extracellular signals with gene expression regulation. Moreover, JMJD3 is also induced by 
retinoic acid, the ligand of another member of the nuclear receptor superfamily, in neural stem 
cells.51 
Several findings indicate that 1,25(OH)2D3-regulated JmjC domain-containing 
proteins are interesting candidates for future studies. JARID2 is a novel subunit of the 
Polycomb repressive complex 2 that is essential for its binding to target genes and required 
for the recruitment of Polycomb repressive complex 1 in mouse embryonic stem cells.52-55 HR 
functions as a VDR corepressor in the skin that interacts with histone deacetylases and 
regulates Wnt signaling.56-59 JMJD5 is required for breast cancer cell proliferation, while 
JMJD6 overexpression enhanced angiogenic sprouting in endothelial cells.60,61 There is scarce 
literature for several of these genes as the research on the biological role of this class of 
epigenetic modulators is still in its infancy. Overall, our results indicate a plausible 
combinatorial action of JMJD3 demethylase and other JmjC domain-containing enzymes on 
the fine-tuning of the gene regulatory activity of 1,25(OH)2D3. 
Given the key role played by ZEB1 in the induction of EMT in several cell 
systems,62,63 we have investigated the mechanism of its regulation by JMJD3 in SW480-ADH 
cells. ZEB1 RNA levels were higher in cells expressing a short-hairpin RNA (shRNA) against 
JMJD3 (shJMJD3 cells) than in those expressing a scrambled shRNA (shControl cells) in 
both the absence and presence of 1,25(OH)2D3 (Figure 2A). Consistently, shJMJD3 cells had 
higher content of ZEB1 protein than shControl cells (Figure 2B). ZEB1 expression is strongly 
downregulated by microRNAs (miRNAs) of the miR-200 family.64,65 To explore whether 
these miRNAs could mediate the effect of JMJD3 on ZEB1 expression, we measured the 
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levels of miR-200b and miR-200c in shJMJD3 and shControl cells. Supporting this 
hypothesis, lower expression of both miR-200b and miR-200c was found in shJMJD3 cells 
compared to shControl cells (Figure 2C). As a negative control, the expression of miR-128, a 
miRNA unrelated to EMT, was unaffected by JMJD3 depletion (Figure 2C). 
The regulatory effect of 1,25(OH)2D3 on the expression of JMJD3 suggests changes in 
H3K27 methylation. However, the analysis of the cellular levels of global H3K27me3 did not 
reveal alterations upon 1,25(OH)2D3 treatment (Figure 3A) or following expression of a 
mutant JMJD3 (Figure 3B) or by JMJD3 knockdown (Figure 3C). These results agree with 
those obtained for Jmjd3 in mouse macrophages and for JMJD6 in human endothelial cells. 
Thus, De Santa et al.41 demonstrated that although neither Jmjd3 induction nor Jmjd3 
depletion caused any detectable modification in the global levels of H3K27me3, Jmjd3 
induction by LPS coincides with H3K27me3 downregulation and with Jmjd3 occupancy at 
the Bmp2 gene promoter. Similarly, Boeckel et al.61 did not observe changes in global histone 
methylation patterns in JMJD6-deficient cells, but they did not rule out the possibility that 
histone modifications might occur at specific promoters. Altogether, these results suggest that 
effects on H3K27 methylation must be analyzed at the single gene level. Furthermore, it must 
be considered that the level of H3K27 methylation also depends on the enzymes that 
methylate this residue: the HMTs of the Polycomb group.66,67 
JMJD3 and, possibly, others HDMs may control 1,25(OH)2D3 target gene expression 
and its antitumoral action by histone demethylation-dependent and/or -independent 
mechanisms (Figure 4). First, JMJD3 may contribute to a local chromatin environment that 
facilitates the expression of 1,25(OH)2D3 target genes via H3K27 demethylation. This has 
been previously demonstrated for the induction of the Bmp2 gene by LPS in mouse 
macrophages.41 Therefore, JMJD3 may be recruited to the regulatory region of 1,25(OH)2D3 
target genes, such as CYP24A1, CDH1/E-cadherin and CST5/cystatin D, and execute 
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epigenetic changes that would facilitate gene transcription activation. In line with this, 
dynamic modification of H3K27me3 has recently been reported in the regulation of 
CDKN1A/p21CIP1 by 1,25(OH)2D3 in normal prostate cells.68  
Supporting the second mechanism, a ChIP-Seq study conducted by Dr. Natoli’s group 
suggested that the involvement of Jmjd3 in tuning transcriptional regulation by LPS in mouse 
macrophages is largely independent of its H3K27 demethylase activity.69 Unexpectedly, 
Jmjd3 was found to be located preferentially at gene transcription start sites with upregulated 
H3K4me3, a histone mark associated with active genes or poised for activation. Importantly, 
only a minority of Jmjd3 peaks were associated with neighbouring H3K27me3 peaks, while 
Jmjd3 deletion resulted in defective recruitment of RNA polymerase II but not in altered 
H3K27me3 signals.69 Moreover, the assumption that histones are the only substrate for HDMs 
may be incorrect, as it has been demonstrated that in human cancer cell lines LSD1 interacts 
with and dynamically regulates lysine methylation of the p53 protein, thus repressing p53-
mediated transcriptional activation.70 Therefore, the possibility that non-histone substrates 
and/or non-enzymatic activities of HDMs may mediate the biological actions of these 
enzymes should be considered.71 It is possible that JMJD3, as well as other JmjC domain-
containing enzymes, may engender demethylation of non-histone substrates and/or other 
actions than protein demethylation, and that these unknown functions could account for the 
observed effects in our studies. 
Interestingly, we found that the overexpression of an inactive JMJD3 C-terminal 
region harbouring a point mutation in the iron-binding centre (MUT 1141-1641) in SW480-
ADH cells has an inhibitory effect on the regulation of 1,25(OH)2D3 target genes similar to 
that observed in shJMJD3 cells.37 Although these results would favor a demethylase-
dependent mechanism, it is unknown whether the mutation generates allosteric changes in the 
JMJD3 protein that would circumvent and/or affect other putative unknown functions. In an 
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attempt to clarify this point and taking advantage of the available Jmjd3 ChIP-Seq data in 
mouse macrophages,69 we analyzed in that system if Jmjd3 (upon induction by LPS) is 
recruited to Cyp24a1 and Cdh1 gene loci. These two genes are 1,25(OH)2D3 targets whose 
induction is reduced by JMJD3 knockdown or by the expression of JMJD3 MUT 1141-1641 
in SW480-ADH cells.37 We found that Jmjd3 binds to a region upstream (40,861) and to two 
regions upstream (41,835 and 39,560) of Cyp24a1 and Cdh1 transcription start sites, 
respectively (Figure 5). These results suggest that JMJD3 may execute epigenetic changes in 
the promoter of these genes to modulate gene expression. However, these data need further 
validation, as they were obtained in a totally different cell system and the number of tags in 
peaks is low.   
Our results show that 1,25(OH)2D3 exerts a complex regulatory effect on the RNA 
expression of a series de HDMs, some of which are induced while others are repressed. 
Furthermore, we have uncovered the epigenetic regulator JMJD3 as a new 1,25(OH)2D3 target 
gene that, in turn, integrates with the gene regulatory actions of this hormone. DNA 
methylation has been proposed as part of the mechanism of repression by 1,25(OH)2D3 of 
certain target genes, such as CYP27B1.72 Likewise, 1,25(OH)2D3 induces the expression of 
Gadd45α that promotes epigenetic gene activation by DNA demethylation in Xenopus 
laevis.73 However, our work demonstrates for the first time that a HDM modulates gene 
activation by this hormone. 
 We believe that the reciprocal regulation of JMJD3 and 1,25(OH)2D3 may play a role 
during colorectal tumorigenesis, and potentially offer new therapeutic targets to delay tumor 
progression. Considering a classical epigenetic view, the regulation of JMJD3 by 
1,25(OH)2D3 may be a mechanism to guarantee the correct activation of genes through the 
loss of the repressive H3K27me3 mark. Having in mind the requirement of JMJD3 expression 
for an adequate 1,25(OH)2D3 action, the deregulation in human colon cancer of JMJD3 
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(downregulation)37 and of the Polycomb gene EZH2 (overexpression)74-78 may generate 
resistance to therapy with 1,25(OH)2D3 and its analogs. 
 
Conclusions 
In summary, the new set of data showing the regulation by 1,25(OH)2D3 of numerous HDMs 
may reflect a complex combinatorial modulation, via histone demethylation-dependent and/or 
-independent mechanisms, of the transcription of a wide range of target genes (Figure 4). 
HDMs controlled by 1,25(OH)2D3 supposedly regulate the expression of many genes, of 
which only part might be 1,25(OH)2D3 targets. This amplifies the regulatory action of this 
hormone and may contribute to explain the existence of a number of target genes that lack 
VDR binding sites. Additionally, data demonstrating the effect of JMJD3 depletion on the 
expression of the EMT inducer ZEB1, via the downregulation of mi-R200b and miR-200c, 
point out to a new mechanism by which 1,25(OH)2D3 may inhibit colon cancer progression. 
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Figure legends 
Figure 1. Effect of 1,25(OH)2D3 on the expression of the genes encoding LSDs and nineteen 
JmjC domain-containing enzymes in SW480-ADH human colon cancer cells. qRT-PCR 
analysis of RNA levels in SW480-ADH cells treated with 100 nM 1,25(OH)2D3 or vehicle for 
4 or 48 h. qRT-PCR assays were performed as described in reference 37 and the sequences of 
the primers used are displayed in Supplementary Table 1. SDHA was used for normalization. 
Data are expressed as the fold-change over vehicle-treated cells. Mean ± SEM (n = 3). The 
statistical significance was assessed by the Student t test (***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 
0.05; n.s., p > 0.05). 
 
Figure 2. JMJD3 knockdown increases the expression ZEB1 and represses miR-200b and 
miR-200c. (A) qRT-PCR analysis of the RNA levels of ZEB1 in SW480-ADH shControl and 
shJMJD3 cells treated with 100 nM 1,25(OH)2D3 or vehicle for 8 or 48 h. qRT-PCR assays 
were performed as described in reference 37 and the sequences of the primers used are 
displayed in Supplementary Table 1. SDHA was used for normalization. Mean ± SEM (n = 3). 
(B) Western blot analysis of ZEB1 protein expression in SW480-ADH shControl and 
shJMJD3 cells treated with 100 nM 1,25(OH)2D3 or vehicle for 8 or 48 h. Western blot assays 
were performed as indicated in reference 37 using antibodies against ZEB1 and lamin B (sc-
10572 and sc-6216, Santa Cruz Biotechnology). Lamin B was used as a loading control. 
Graph shows the mean ± SEM (n = 3). (C) qRT-PCR analysis of the RNA levels of miR-200b 
and miR-200c in SW480-ADH shControl and shJMJD3 cells. RNA was extracted with the 
miRNeasy Mini Kit (217004, Qiagen) and reverse transcribed using the corresponding primer 
and the TaqMan MicroRNA Reverse Transcription Kit (4366596, Applied Biosystems). The 
following TaqMan probes were used: miR-200b (002251), miR-200c (002300), miR-128 
(002216) and RNU44 (001094) (Applied Biosystems). RNU44 small nucleolar RNA was used 
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for normalization and miR-128 as a negative control. Mean ± SEM (n = 3). (A-C) The 
generation of SW480-ADH shControl and shJMJD3 cells was previously described in 
reference 37. The statistical significance was assessed as indicated in the legend to Figure 1.   
 
Figure 3. JMJD3 does not affect the global level of H3K27me3 in SW480-ADH cells. (A) 
Western blot analysis of H3K27me3 in SW480-ADH cells treated with the indicated 
concentrations of 1,25(OH)2D3 for 72 or 96 h. (B) Western blot analysis of H3K27me3 levels 
in Mock, WT 1141-1641 and MUT 1141-1641 SW480-ADH cells treated with 100 nM 
1,25(OH)2D3 or vehicle for 48 h. The generation of Mock, WT 1141-1641 and MUT 1141-
1641 SW480-ADH cells was previously described in reference 37. (C) Western blot analysis 
of H3K27me3 levels in SW480-ADH shControl and shJMJD3 cells treated with 100 nM 
1,25(OH)2D3 or vehicle for 8 or 48 h. The generation of SW480-ADH shControl and 
shJMJD3 cells was previously described in reference 37. (A-C) Western blot assays were 
performed as indicated in reference 37 using antibodies against total H3 (ab1791, Abcam) and 
H3K27me3 (9733, Cell Signaling). Total histone H3 was used as a control. Graphs show the 
mean ± SEM (n = 3). The statistical significance was assessed as indicated in the legend to 
Figure 1. All comparisons were found not significant (p > 0.05). 
 
Figure 4. 1,25(OH)2D3 regulates the expression of JMJD3 and other HDMs that, in turn, 
mediate the antitumoral effects of 1,25(OH)2D3 in colon cancer. HDMs may modulate 
1,25(OH)2D3 action by demethylation-dependent and/or -independent effects on the 
expression of: (i) 1,25(OH)2D3 target genes, (ii) EMT inducers, and/or (iii) other unknown 
targets. 
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Figure 5. Jmjd3 binding to Cyp24a1 (A) and Cdh1 (B) gene loci in LPS-stimulated mouse 
macrophages. Jmjd3 ChIP-Seq peak data for mouse Chr 2 and 8 from reference 69 were 
converted to bedGraph format and overlaid on mouse genome assembly (mm8) as a custom 
track using the UCSC genome browser. Peak height represents the number of overlapping 
tags observed in that region and width of peak suggests the area covered by the tags. 
 25
Tables 
Supplementary Table 1. Sequence of the primers used for qRT-PCR. 
Gene Forward primer Reverse primer 
HIF1AN CCCCTTCTGCTTGTCTTCAG GAAATGCCCTCAAAGTGCTC 
HR CACAGGACCAAGAGCATCAA AGCAGTTCGCAGAGAGAAGG 
HSPBAP1 TCAGAATGGGGATGAAAAGC TGGTCACAGTTCCAGGTCAG 
JARID2 AAGGAGGTGCTGATGGAGAA AGAGGGTGGAACTTGTGGTG 
JMJD5 ACATCAGCATCCCCGACTAC TACTTCCTCCCCATCACCTG 
JMJD6 CCAACTTCCCTGTGGTATGG GGGTGCTCTTGCTTCAAAAT 
JMJD8 GCTTTGGAATCGCAGGAG GCGTCTTCTCAGGTGGGTAA 
KDM2B AGTCACCAAGGAAGGCTGTG AAAGGAAAGTGTCGGCTCAC 
KDM3B AACTTCCTCAAACCCCCTTG TTGCTCTTCACTCCTGCTGA 
KDM4A GCAAGAAAAGAAACGGCAAC ACCCTGGAAGCACCTACTCC 
KDM4B CGCTCTTCTACCCCTACTGC GTCTTCTGACGGCTTTTGGA 
KDM4C CACAAGCCAGATAGCAGCAA CCCTCCGATGTAACGACTTC 
KDM4D TGAACGCTATGACCTGTGGA GCTGCTCTCCTGGGTAACTG 
KDM5A TGAACGATGGGAAGAAAAGG TGGGTAGAAAGGCTGGAATG 
KDM5B TGCTTTCGTCAGGGAATCTT ATGATGTTGTGCCAGGAGGT 
KDM5D AAACATTGGCTCCCTGCTAC GATGCTGTGGGGCTTGTATT 
LSD1 GTGTGTGCCTGTGGCTTTAG GACTCGTGGAGCGGGTATT 
LSD2 CCTGGAAGCCAAAGACAGAA CACGAGCGAGCAGATACTTG 
NO66 CGAGGAACTGGCTCTGACAT CCCGAGGAAAATACAGCAAA 
PHF8 GGATTTGCCTGGATTTTGAA AGGGTTATCTGCGTCATTGG 
PLA2G4B GCCTCCATTTCCACAAAGAC AGGTAGCCAACATCCAGCAG 
SDHA TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG
ZEB1 GCCAATAAGCAAACGATTCTG TTTGGCTGGATCACTTTCAAG 
 





